Bloomberg Reported Saturday: Danaher Interested In Buying Life Sciences Firm Catalent, Though Deal Is Not Imminent
https://www.bloomberg.com/news/articles/2023-02-04/danaher-is-said-to-be-interested-in-life-sciences-firm-catalent
5 On-The-Money Stock Picks For Last Week From Benzinga’s Most Accurate Analysts
US stocks closed mostly higher on Friday, with the Nasdaq gaining more than 100 points during the session.
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
Danaher (NYSE:DHR) has outperformed the market over the past 5 years by 13.99% on an annualized basis producing…
Cowen & Co. Maintains Outperform on Danaher, Lowers Price Target to $320
Cowen & Co. analyst Dan Brennan maintains Danaher (NYSE:DHR) with a Outperform and lowers the price target from $340 to $320.
Baird Maintains Outperform on Danaher, Raises Price Target to $321
Baird analyst Catherine Schulte maintains Danaher (NYSE:DHR) with a Outperform and raises the price target from $315 to $321.
Barclays Maintains Overweight on Danaher, Raises Price Target to $290
Barclays analyst Luke Sergott maintains Danaher (NYSE:DHR) with a Overweight and raises the price target from $277 to $290.
Danaher Q4 Adj. EPS $2.87 Beats $2.51 Estimate, Sales $8.37B Beat $7.88B Estimate
Danaher (NYSE:DHR) reported quarterly earnings of $2.87 per share which beat the analyst consensus estimate of $2.51 by 14.34 percent. This is a 6.69 percent increase over earnings of $2.69 per share from the same period
Earnings Scheduled For January 24, 2023
Companies Reporting Before The Bell
• GATX (NYSE:GATX) is expected to report quarterly earnings at $1.44 per share on revenue of $327.63 million.
Danaher Corp – For Q4 2022, Estimated Revenues Are Anticipated To Increase In Low-Single Digit % Range YoY; Expects Q4 Estimated Non-GAAP Core Revenue Growth In High Single Digit % Range
Danaher Corporation (NYSE:DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2022